February 23, 2024 duration: 3 min

Enhanced purification services for diverse projects

In the dynamic landscape of antibody research and therapeutics, having a diverse array of purification methods is essential. At Evitria AG, we recognize the need for flexibility to meet various project requirements. Let’s delve into our updated purification services.

February 19, 2024 duration: < 1 min

Dr. Desmond Schofield new CBO of evitria

Dr. Desmond Schofield, has been appointed Chief Business Officer as of 1st January 2024.

February 13, 2024 duration: 5 min

Therapeutic antibodies: afucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity (ADCC)

Therapeutic antibodies are the fastest-growing class of biological drugs. Their ability to interact with specific targets means they can be employed for a range of diseases, including cancer, autoimmune and infectious diseases.

February 6, 2024 duration: 2 min

Scalability & Reproducibility – getting it right first time, then again and again…

Delivering material with the same quality at every scale, and with several years in between campaigns, enabled our client to rapidly move through development stages without having to undertake difficult troubleshooting activities or worry about their material quality.

January 22, 2024 duration: 2 min

Antibody reformatting and engineering – where will your variable domains take you?

The design of your antibody sequence is the single most important step in your therapeutic development journey. Weak binding, off-target effects, and insufficient activity can all improve via sequence engineering.

December 6, 2023 duration: 4 min

Transient antibody expression in CHO cells: Our approach at evitria

At evitria, we are specialized in transient transfection of CHO cells to produce recombinant antibodies. Find out more about our approach in this article.

Recommended articles

February 29, 2024 duration: 9 min

An Introduction to Recombinant Antibodies: 7 Key Insights

From the application in medicine and science to recombinant antibody production and the advantages of recombinant Abs in contrast to traditional monoclonal antibodies, this article will teach you all you need to know about recombinant antibodies.

Desmond Schofield

Desmond Schofield

Director of Business Development at evitria
November 21, 2023 duration: 6 min

Afucosylated recombinant antibodies

Generally speaking, antibodies of any kind, including recombinant and afucosylated antibodies, are Y-shaped proteins produced by the human body. As they are able to identify and neutralize foreign objects – in other words viruses – they play a major contributing role in keeping our body and immune system healthy.

Desmond Schofield

Desmond Schofield

Director of Business Development at evitria
September 30, 2021 duration: 6 min

Antibody-Dependent Cellular Cytotoxicity (ADCC) – definition, mechanism & application

Antibody-dependent cellular cytotoxicity is a key process of the immune system’s arsenal to ward off cancerous cells and infections. We show you important definitions and the ADCC mechanism and key facts on ADCC antibodies in this post.

Desmond Schofield

Desmond Schofield

Director of Business Development at evitria
Get in Touch